Pharmozyme to Present at the AACC Annual Meeting & Clinical Lab Expo 2017
Sunnyvale, CA, July 31, 2017 (Newswire.com) - Pharmozyme, Inc. (Pharmozyme), a manufacturer of contamination free enzymes, including Crystal Taq, the world’s first Taq Polymerase free from bacterial and animal DNA contamination, announced that it will present Pharmozyme's new platform for the pure production of such enzymes at the 2017 American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo.
The conference will be held July 30 - August 3 in San Diego, California, at the San Diego Convention Center. Dr. Nader Nourizad, Pharmoyzme’s Chief Executive Officer, will be giving his presentation on August 1st, Tuesday, at 10 a.m. in Theater 3. Pharmozyme will be operating booth number 514, Hall A, in the Exhibitors section. At its booth, visitors will be able to learn about Pharmozyme’s new EG PCR Master Mix (2X), containing EvaGreen, a next-generation DNA binding dye with properties ideal for use in qPCR, RT-PCR and other PCR based applications. Pharmozyme’s master mixes are made with Crystal Taq polymerase.
“Pharmozyme is set to become the de-facto standard and a ‘must have’ for every DNA amplification & sequencing research facility,” said Dr. Nader Nourizad, Chief Executive Officer for Pharmozyme. “As we look to the future, our highly pure enzymes will disrupt the in vitro diagnostics markets by reducing the number of inaccurate testing results from contamination impacting clinical, industrial, and research pathogen testing.”
About Pharmozyme
Pharmozyme has developed a proprietary technology to produce the world’s purest reagents, including the world’s first Taq Polymerase free from bacterial and animal DNA contamination. With its storefront PCRShop.com, Pharmozyme manufactures and sells its enzymes that are used for supporting new technologies in DNA Amplification, Sequencing research, and production of highly accurate and sensitive pathogen detection kits. In the near future, Pharmozyme plans to produce its own versions of highly accurate and sensitive kits for medical diagnostics. For more information, visit www.pharmozyme.com.
© Pharmozyme, Inc. 2017
Legal Disclaimer
This press release includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "is set to become", "anticipates", "expects", "intends", "may", "will", “plans”, or "should", and include statements Pharmozyme makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Pharmozyme's actual results may differ materially from those predicted by the forward-looking statements. Pharmozyme undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
Media Contact
Pharmozyme, Inc.
Michael Swartzburg, Chief Financial Officer
1190 Mountain View Alviso Rd, Suite H
Sunnyvale, CA 94089
+1 669-600-3194
Source: Pharmozyme, Inc.
Share:
Tags: AACC, clinical, contamination, enzyme, free, PCR, polymerase, Taq
